AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 12 min read$HELP

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 2:35 p.m. EDT. The webcast will be available live, with a replay on the company’s investor relations site.

Original reporting
manilatimes.net
Published Jun 1, 2026, 12:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 12:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York — source image
Source · manilatimes.net
Decision brief

The 30-second read

$HELPNeutralLow
01

Why it matters

This announcement primarily sets expectations for management visibility at a healthcare conference; it does not disclose new efficacy/safety, FDA/other regulatory actions, or financing/partnership terms.

02

Market read

Potential for sentiment drift into the webcast, but no actionable new fundamentals are provided in the release.

03

What to watch

Watch for any subsequent press release or investor deck tied to the fireside chat; absent that, the scheduling news is unlikely to re-rate the stock.

Relevance 4/10Novelty 3/10Timing: Ahead of the June 4, 2:35 p.m. EDT fireside chat webcast

Background

Helus Pharma (commercial operating name of Cybin Inc.) is a clinical-stage serotonergic agonist developer with programs including HLP003 (Phase 3, adjunctive MDD) and HLP004 (Phase 2, GAD).

Company-level read

Ticker impact

$HELPNeutralHigh confidence
Context

Helus Pharma (HELP) announced interim CEO Eric So will present at the Jefferies Global Healthcare Conference, with a webcast scheduled June 4.

Expected impact

Low near-term impact; any price move would likely depend on what is said during the fireside chat, not disclosed here.

Evidence & confidence

The article is purely an investor-conference scheduling update and does not provide incremental results, guidance, or deal/regulatory outcomes.

Market effects

Sector

Minimal; conference participation is common for biotech and does not change sector fundamentals by itself.

Regional

Minimal; the event is in New York but the company’s operations are multi-region.

Global

Low; no international regulatory or partnership developments are mentioned.

Counterpoint

What could challenge this read

Traders may treat the event as a potential venue for incremental trial updates; however, this specific release does not include any such information.

Key entities

  • executive
    Eric So

    Interim CEO of Helus Pharma scheduled to participate in the Jefferies fireside chat.

  • event
    Jefferies Global Healthcare Conference

    New York conference (June 2-4, 2026) where the webcast will be available June 4 at 2:35 p.m. EDT.

Read at source← All news

Related articles

AUG 14
$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

finanznachrichten.de6 min
JUL 21
$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min
JUL 17
$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min
JUN 25
$HELPMedAI 8/10

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

montrealgazette.com2 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min